DDInter1913 DDInter122
Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene. Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Valproic acid {u} (Compound) resembles {v} (Compound) Anisotropine Methylbromide
Valproic acid {u} (Compound) treats {v} (Disease) epilepsy syndrome
Valproic acid {u} (Compound) binds {v} (Gene) CYP3A4
Valproic acid {u} (Compound) palliates {v} (Disease) endogenous depression
Valproic acid {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Central Nervous System Disorganized Electrical Activity
Valproic acid {u} (Compound) causes {v} (Side Effect) Photosensitivity
Valproic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Valproic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Valproic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentoxyverine
Valproic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Valproic acid (Compound) resembles Anisotropine Methylbromide (Compound)
Valproic acid (Compound) treats epilepsy syndrome (Disease)
Valproic acid (Compound) binds CYP3A4 (Gene)
Valproic acid (Compound) palliates endogenous depression (Disease)
Valproic acid (Compound) is included by Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class)
Valproic acid (Compound) causes Photosensitivity (Side Effect)
Valproic acid may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Valproic acid may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli